Patient and disease characteristics
| Patient ID . | Gender . | Age (y) . | Time posttransplantation (y) . | Type of transplantation . | Disease before HCT . | Therapy . |
|---|---|---|---|---|---|---|
| #175 | M | 68 | 9 | allo | CLL | Mycophenolate mofetil |
| #181 | M | 48 | 11.8 | allo | CLL | — |
| #184 | F | 48 | 3.6 | allo | AML | Steroids and Bruton tyrosine kinase inhibitor |
| #211 | M | 48 | 0.4 | allo | AML | Calcineurin inhibitor |
| #214 | M | 71 | 5.9 | allo | MDS | — |
| #216 | F | 70 | 6.9 | allo | MFI | — |
| #218 | M | 65 | 0.8 | allo | ALL | — |
| #219 | F | 66 | 0.5 | allo | CLL | Calcineurin inhibitor |
| #228 | M | 59 | 1 | auto | MM | Lenalidomide |
| Patient ID . | Gender . | Age (y) . | Time posttransplantation (y) . | Type of transplantation . | Disease before HCT . | Therapy . |
|---|---|---|---|---|---|---|
| #175 | M | 68 | 9 | allo | CLL | Mycophenolate mofetil |
| #181 | M | 48 | 11.8 | allo | CLL | — |
| #184 | F | 48 | 3.6 | allo | AML | Steroids and Bruton tyrosine kinase inhibitor |
| #211 | M | 48 | 0.4 | allo | AML | Calcineurin inhibitor |
| #214 | M | 71 | 5.9 | allo | MDS | — |
| #216 | F | 70 | 6.9 | allo | MFI | — |
| #218 | M | 65 | 0.8 | allo | ALL | — |
| #219 | F | 66 | 0.5 | allo | CLL | Calcineurin inhibitor |
| #228 | M | 59 | 1 | auto | MM | Lenalidomide |
ALL, acute lymphoblastic leukemia; allo, allogeneic; AML, acute myeloid leukemia; auto, autologous; CLL, chronic lymphocytic leukemia; F, female; M, male; MDS, myelodysplastic syndromes; MFI, myelofibrosis; MM, multiple myeloma; –, no therapy.